Panelists:
Zoltán Gulyás
Senior Field Applications Scientist
Repligen
Panelist
Zoltán Gulyás
Zoltán Gulyás is a senior field applications scientist for the TFF systems and filters at Repligen, providing technical support to customers in Western and Southern Europe.
Gulyás has an MSc degree in chemical engineering from the University of Technology and Economics in Hungary and has been in the field of pharma and biopharma industries for more than 15 years. He started his career at Gedeon Richter in Hungary as a process development scientist, where he worked on the purification of small molecules, peptides, monoclonal antibodies, and other recombinant proteins. After eight years, he joined Thermo Fisher Scientific as a Field Applications Scientist for the POROS and CaptureSelect resin portfolios and supported customers in Northern and Southern Europe before joining Repligen in 2021.
Nigel Herbert
North America FAS Manager, Process Analytics
Repligen
Panelist
Nigel Herbert
Nigel Herbert is a dedicated advocate for customer success. With a Bachelor of Science degree in Biomaterials Engineering and a minor in Chemistry from Alfred University, he brings a wealth of skills to his role as an FAS Manager at Repligen.
Since joining the team in 2019, Herbert has been on the forefront of advancing customers’ analytical methods. He specializes in UV-Vis spectroscopy, analytical processes, and method validation, offering invaluable support to ensure the highest standards of precision and reliability.
Herbert’s collaborative spirit has resulted in numerous published application notes. Through close partnerships with Repligen customers, he has made significant strides in solving complex challenges and driving innovation in the biotechnology field. His unwavering commitment to enhancing analytical capabilities exemplifies Repligen’s dedication to success.
- Time:
Antibody-drug conjugates (ADCs) represent a promising new therapeutic modality, delivering targeted, potent therapies directly to cancerous cells and offering hope for millions of patients worldwide. However, ADC manufacturing remains a complex, multi-step process with inherent challenges. Both early- and late-stage manufacturers must navigate the intricacies of handling highly potent payloads, maintaining consistent drug-antibody ratios (DAR), minimizing operator exposure, and ensuring product efficacy and safety.
In this GEN webinar, our expert speakers Zoltán Gulyás and Nigel Herbert will explore how next-generation technologies can help ADC manufacturers overcome these hurdles. Through three real-world case studies, you’ll learn how these innovative technologies can help to:
- Accelerate processing time and minimize risk to product and operators during tangential flow filtration (TFF)
- Maintain product consistency and operator safety while minimizing extractables and leachables
- Drive process efficiency and reduceturnaround time with accurate, real-time DAR measurement
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post ADC Manufacturing: Driving Process Productivity and Reducing Risk appeared first on GEN – Genetic Engineering and Biotechnology News.
